Abstract: Evaluation of a New Concept in Two-Stage Breast Reconstruction: Patient Controlled Tissue Expansion using the AeroForm CO2 Tissue Expander System

ConClusion: We present a validated risk stratification tool for predicting 30-day SSM following reduction mammoplasty using data that are readily available to the clinician. This may allow targeted screening and intervention in high-risk patients, better counseling, selective resident participation, and ultimately decrease overall health-care costs. This is the first study to date that provides a well-defined risk assessment tool to improve outcomes in reduction mammoplasty patients. Future studies should determine if implementation of our SSM risk score optimizes safety and reduces morbidity rates after reduction mammoplasty.